Provided by Tiger Trade Technology Pte. Ltd.

Amgen

349.39
+1.170.34%
Post-market: 350.481.09+0.31%19:42 EDT
Volume:1.98M
Turnover:691.18M
Market Cap:188.14B
PE:24.55
High:351.25
Open:346.63
Low:346.60
Close:348.22
52wk High:391.29
52wk Low:261.43
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.83
T/O Rate:0.37%
Dividend:9.66
Dividend Rate:2.76%
EPS(TTM):14.23
EPS(LYR):14.23
ROE:106.10%
ROA:7.93%
PB:21.73
PE(LYR):24.55

Loading ...

Zai Lab, Amgen partner on global trial of DLL3 ADC with Imdelltra in SCLC

Reuters
·
Apr 01

Zai Lab Ltd - Announces Global Clinical Trial Collaboration With Amgen for Es-Sclc

THOMSON REUTERS
·
Apr 01

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

TIPRANKS
·
Apr 01

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

TIPRANKS
·
Apr 01

Genmab names Margarida Duarte general manager for Europe and emerging markets

Reuters
·
Apr 01

Amgen announces availability of 2025 shareholder letter and annual report

Reuters
·
Apr 01

Amgen publishes 2025 annual report, revenue rises 10% to $37 billion

Reuters
·
Apr 01

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

TIPRANKS
·
Apr 01

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Dow Jones
·
Mar 31

FDA: Vanishing Bile Duct Syndrome & Drug-Induced Liver Injury Cases With Fatal Outcomes Represent New Safety Concerns for Tavneos - Website

THOMSON REUTERS
·
Mar 31

REFILE-FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies

Reuters
·
Mar 31

Amgen Says Repatha Reduced Major Cardiovascular Event Risk by 31% in Diabetes Patients

MT Newswires Live
·
Mar 30

Amgen announces data on Repatha from Phase 3 Vesalius-CV trial

TIPRANKS
·
Mar 29

Amgen says Repatha cuts first major cardiovascular events 31% in VESALIUS-CV subgroup

Reuters
·
Mar 29

BRIEF-Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients

Reuters
·
Mar 29

Amgen: Phase 3 Vesalius-Cv Clinical Trial Showed Repatha Reduced Risks of Heart Attack, Coronary Heart Disease Death, Ischemic Stroke

THOMSON REUTERS
·
Mar 29

Amgen: Repatha Cuts Risk of First Major Cardiovascular Event by 31% in High-Risk Patients Without Known Significant Atherosclerosis

THOMSON REUTERS
·
Mar 29

Takeda's psoriasis pill succeeds in late-stage studies

Reuters
·
Mar 29

Amgen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 28

Ema's Chmp: Joenja (Leniolisib) Received Positive Opinion for Marketing Authorisation Under Exceptional Circumstances

THOMSON REUTERS
·
Mar 27